Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Ranjan, T; Peters, KB; Vlahovic, G; Alderson, LM; Herndon, JE; McSherry, F; Threatt, S; Sampson, JH; Friedman, AH; Bigner, DD; Friedman, HS; Vredenburgh, JJ; Desjardins, A

Published Date

  • May 20, 2013

Published In

Volume / Issue

  • 31 / 15

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference Location

  • Chicago, IL

Conference Start Date

  • May 31, 2013

Conference End Date

  • June 4, 2013